Article: ACPA Antibodies Titer at the Time of Rheumatoid Arthritis Diagnosis Is Not Associated with Disease Severity.
The Israel Medical Association journal : IMAJ
2021 Volume 23, Issue 10, Page(s) 646–650
Abstract: Background: Rheumatoid arthritis (RA) is a chronic inflammatory and destructive joint disease with the presence of autoantibodies, rheumatoid factor (RF), and anti-citrullinated protein antibodies (ACPA). The presence of RF or ACPA predicts RA severity. ...
| Abstract | Background: Rheumatoid arthritis (RA) is a chronic inflammatory and destructive joint disease with the presence of autoantibodies, rheumatoid factor (RF), and anti-citrullinated protein antibodies (ACPA). The presence of RF or ACPA predicts RA severity. Data on the influence of ACPA titer on RA course are limited. Objectives: To determine the correlation between ACPA titers at the time of RA diagnosis to RA features and severity during 3 years of follow-up. Methods: We performed a retrospective study of RA patients treated at our institution during the years 2006-2015 with known ACPA titers at RA diagnosis who completed at least 3 years of follow-up. Patients (N=133) were divided according to ACPA titer: seronegative (< 15 U/ml, n=55), weakly positive (15-49 U/ml, n=18), moderately positive (50-300 U/ml, n=29), and strongly positive (> 300 U/ml, n=31). Patient data, including disease activity score (DAS28), bone erosion on hand and/or foot X-rays, treatments with corticosteroids and disease-modifying-anti-rheumatic drugs (DMARDs), and hospitalizations, were recorded. Chi-square and Mann-Whitney method were used for statistical analysis. P < 0.05 was considered as statistically significant. Results: Male gender, smoking, and RF positivity correlated with ACPA positivity and higher ACPA titers. There was no correlation between ACPA titer and the variables defined as representing RA severity: higher DAS28, bone erosions, hospitalizations, need for corticosteroids, and conventional and biological DMARDs. Conclusions: Titer of ACPA was not identified as a predictive factor for RA severity. |
|---|---|
| MeSH term(s) | Adrenal Cortex Hormones/therapeutic use ; Anti-Citrullinated Protein Antibodies/blood ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/epidemiology ; Arthritis, Rheumatoid/immunology ; Correlation of Data ; Disease Progression ; Female ; Humans ; Israel/epidemiology ; Male ; Middle Aged ; Monitoring, Immunologic/methods ; Monitoring, Immunologic/statistics & numerical data ; Negative Results ; Patient Acuity ; Predictive Value of Tests ; Prognosis ; Radiography/methods ; Radiography/statistics & numerical data ; Retrospective Studies ; Rheumatoid Factor/blood ; Severity of Illness Index |
| Chemical Substances | Adrenal Cortex Hormones ; Anti-Citrullinated Protein Antibodies ; Antirheumatic Agents ; Rheumatoid Factor (9009-79-4) |
| Language | English |
| Publishing date | 2021-10-21 |
| Publishing country | Israel |
| Document type | Journal Article |
| ZDB-ID | 2008291-5 |
| ISSN | 1565-1088 ; 0021-2180 |
| ISSN | 1565-1088 ; 0021-2180 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5470: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.